Biologics versus immunomodulators or antibiotics for the management of fistulizing Crohn's disease a review of comparative clinical effectiveness and cost-effectiveness

This report is part of a series of reviews CADTH is conducting on the effectiveness of treatment strategies for patients with inflammatory bowel disease (both Crohn's disease and ulcerative colitis). The purpose of the current report is to evaluate the clinical and cost-effectiveness of biologi...

Full description

Bibliographic Details
Main Authors: Young, Calvin, Campbell, Kaitryn (Author)
Corporate Authors: Canadian Agency for Drugs and Technologies in Health, Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format: eBook
Language:English
Published: Ottawa (ON) CADTH March 29, 2019, 2019
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:This report is part of a series of reviews CADTH is conducting on the effectiveness of treatment strategies for patients with inflammatory bowel disease (both Crohn's disease and ulcerative colitis). The purpose of the current report is to evaluate the clinical and cost-effectiveness of biologics (i.e., adalimumab, infliximab, and vedolizumab) compared with immunomodulators or antibiotics for the management of fistulizing Crohn's disease
Physical Description:1 PDF file (34 pages) illustrations